Abstract:525 Objectives The mesenchymal epithelial transition (c-Met) factor overexpression has been widely accepted as a potent biomarker for various of cancers such as glioblastoma, breast cancer, colorectal cancer, etc. c-Met inhibitor, which targets c-Met and further interferes with downstream signaling pathways, could serve as both diagnostic and therapeutic molecule by specifically binding with c-Met receptors. Until now small molecule based probes for c-Met imaging has not been reported. In previous studies, we have successfully synthesized c-Met inhibitor C21b with high c-Met receptor binding and suppressing functions and validated its tumor suppression capability. In the present study, we aim to develop a 68Ga labeled, C21b based PET probe for imaging of c-Met positive tumors such as glioblastoma which realize the potential for both glioblastoma detection and cancer therapy evaluation. Methods C21b molecule with NODAGA chelator was obtained through chemical synthesis and confirmed by MS and 1H-NMR. The resulting conjugate NODAGA-C21b was radiolabeled with 68Ga in 0.1N sodium acetate (pH 5.5) at 55 oC within 15 min. The PET probe was then characterized by HPLC analysis and subjected to mouse serum stability assay. The cell uptake and binding affinity tests of 68Ga-NODAGA-C21b were conducted using U87MG glioblastoma cells. Small animal PET imaging and biodistribution analysis were conducted on mice with c-Met overexpression (U87MG) and low expression (OVCAR3) tumor xenograft models (n=4 per group) after injection of approximately 7.4 MBq of 68Ga-NODAGA-C21b for up to 2 h after injection. Results 68Ga-NODAGA-C21b was successfully synthesized in high radiochemical purify (>99%) and yield (>98%) and demonstrated high stability in mouse serum for up to 2 h incubation. U87MG cells showed increased uptake of 68Ga-NODAGA-C21b tracer with longer incubation time (from 9.6 % at 15 min to 14.2 % at 2 h incubation). The uptake could be effectively reduced by excess unlabeled C21b and c-Met inhibitor Crizotinib (14.2 % vs. 2.4 % and 2.3 % for self-blocking and Crizotinib blocking, respectively, after 2 h incubation). Binding affinity assays revealed the Kd was 2.88 nM for U87MG cells. Small animal PET/CT imaging showed that 68Ga-NODAGA-C21b accumulated in U87MG tumor and retained at similar level during the 2 h monitoring (0.63, 0.46 and 0.45 %ID/g at 30, 60 and 120 min post injection). However, in OVCAR3 tumor, the signal was significantly lower from beginning and decreased dramatically afterwards (0.47, 0.26 and 0.20 %ID/g at 30, 60 and 120 min post injection). Biodistribution results exhibited that Tumor/Muscle (T/M) signal ratio increased from 3.18 to 4.15 in U87MG model at 2 h post injection time point while T/M ratio decreased from 2.29 to 1.66 in OVCAR3 model. And Tumor/Brain (T/B) signal ratio was higher in U87MG model than that of in OVCAR3 model at all three time points (2.53 vs. 1.56, 2.37 vs. 1.36 and 2.39 vs. 1.85). The probe was found to be mainly metabolized through liver and spleen. Conclusions c-Met targeted 68Ga-NODAGA-C21b is a novel small molecule based PET probe for imaging of c-Met overexpression tumors. Its ability to differentiate tumors with high and low c-Met expression in vivo holds the potential for stratification of patients for c-Met targeted cancer therapy. $$graphic_A6B47F64-40EB-4636-AEF2-5EF8FE968326$$

Synthesis and evaluation of 18F labeled crizotinib derivative [18F]FPC as a novel PET probe for imaging c-MET-positive NSCLC tumor

Synthesis and bioevaluation of a novel 99mTc-labeled complex with a crizotinib HYNIC derivative for imaging of c-Met–positive expression

18F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging

68Ga-Labeled Small Molecule Inhibitor for C-Met Targeted Pet Imaging of Tumor.

Novel Dual-Function Near-Infrared II Fluorescence and PET Probe for Tumor Delineation and Image-Guided Surgery.

Pet Imaging of C-Met in Cancer with Cu-64-Labeled Hepatocyte Growth Factor

Detection of colorectal cancer using a small molecular fluorescent probe targeted against c-Met

Preliminary Application of Micro‐spect/ct Imaging by 99mtc‐tricine‐edda‐hynic‐c‐met for Non‐small‐cell Lung Cancer

Synthesis and evaluation of 64 Cu-radiolabeled NOTA-cetuximab ( 64 Cu-NOTA-C225) for immuno-PET imaging of EGFR expression.

Preclinical Evaluation of a Fluorine-18 Labeled Probe for the Detection of the Expression of PSMA Level in Cancer

Exploration of radionuclide labeling of a novel scFv-Fc fusion protein targeting CLDN18.2 for tumor diagnosis and treatment

Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor

PET Imaging of Peptide Probe Al[ 18 F]F-NOTA-PCP1 for Monitoring the Engagement of PD-L1 Antibodies in Tumors

PET imaging of CXCR4 expression using [18F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors

Preclinical Evaluation Of An F-18-Trifluoroborate Methionine Derivative For Glioma Imaging

Synthesis and preclinical evaluation of novel 18 F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts

Preclinical evaluation of an 18 F-trifluoroborate methionine derivative for glioma imaging

Tracing Investigation of Targeting Gastric Cancer with 18F Labeled Anti-Human Epidermal Growth Factor Receptor 2 Specific Affibody Molecule ZHER2:342

Effectiveness of Crizotinib in a Patient with Mesenchymal-Epithelial Transition Overexpression/fluorescence in Situ Hybridization-Negative/next-generation Sequencing-Negative Advanced Lung Adenocarcinoma: a Case Report

Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein

Synthesis, Screening, and Evaluation of Theranostic Molecular CPCR4-Based Probe Targeting CXCR4.